Strategic Partnerships Chembio recently merged with or partnered under Biosynex and has a market footprint through distribution to hospitals, clinics, and public health entities, presenting an opportunity to cross-sell broader rapid diagnostic solutions and integrated testing programs.

Expansion Financing Recent $1.8M CARB-X grant and ongoing financing activity suggest available liquidity and government/biotech funding interest, enabling joint development of rapid tests for infectious diseases and potential co-funded pilot programs.

Public Offering Momentum Past public offering activity and ongoing visibility as a biotech diagnostics player indicate a receptiveness to collaborative pilots with healthcare networks and potential population-scale deployments in underserved markets.

DPP Platform Strength DPP rapid test platform enables multiplexed results and portable on-site use, aligning with opportunities to upsell to clinics and public health labs seeking fast, accurate point-of-care testing and reduced human error.

Market Fit Opportunities Chembio’s focus on HIV, syphilis, typhoid, COVID-19, and other infectious diseases matches rising demand for decentralized, quick-turnaround diagnostics, suggesting sales potential with hospitals, clinics, and government programs expanding point-of-care testing.